GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK N) » Definitions » Cyclically Adjusted Price-to-FCF

GSK (MEX:GSK N) Cyclically Adjusted Price-to-FCF : 8.75 (As of May. 15, 2025)


View and export this data going back to 2003. Start your Free Trial

What is GSK Cyclically Adjusted Price-to-FCF?

As of today (2025-05-15), GSK's current share price is MXN689.12. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN78.77. GSK's Cyclically Adjusted Price-to-FCF for today is 8.75.

The historical rank and industry rank for GSK's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MEX:GSK N' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.11   Med: 12.6   Max: 16.26
Current: 9.58

During the past years, GSK's highest Cyclically Adjusted Price-to-FCF was 16.26. The lowest was 9.11. And the median was 12.60.

MEX:GSK N's Cyclically Adjusted Price-to-FCF is ranked better than
91.08% of 325 companies
in the Drug Manufacturers industry
Industry Median: 30.77 vs MEX:GSK N: 9.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's adjusted free cash flow per share data for the three months ended in Mar. 2025 was MXN8.906. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN78.77 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GSK's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Price-to-FCF Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.16 12.90 10.25 10.50 9.63

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.35 10.91 10.76 9.63 10.30

Competitive Comparison of GSK's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.


;
;

GSK Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GSK's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=689.12/78.77
=8.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=8.906/135.6000*135.6000
=8.906

Current CPI (Mar. 2025) = 135.6000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -2.482 100.100 -3.362
201509 0.505 100.200 0.683
201512 10.736 100.400 14.500
201603 -1.454 100.400 -1.964
201606 10.258 101.000 13.772
201609 16.483 101.500 22.021
201612 28.948 102.200 38.409
201703 8.603 102.700 11.359
201706 4.689 103.500 6.143
201709 17.173 104.300 22.327
201712 29.009 105.000 37.463
201803 6.517 105.100 8.408
201806 12.996 105.900 16.641
201809 20.236 106.600 25.741
201812 43.418 107.100 54.972
201903 4.608 107.000 5.840
201906 9.195 107.900 11.556
201909 25.082 108.400 31.376
201912 32.821 108.500 41.019
202003 8.993 108.600 11.229
202006 33.904 108.800 42.255
202009 3.023 109.200 3.754
202012 43.749 109.400 54.226
202103 -0.324 109.700 -0.400
202106 10.205 111.400 12.422
202109 18.992 112.400 22.912
202112 43.260 114.700 51.143
202203 25.446 116.500 29.618
202206 11.491 120.500 12.931
202209 9.373 122.300 10.392
202212 13.400 125.300 14.502
202303 -5.098 126.800 -5.452
202306 8.166 129.400 8.557
202309 17.983 130.100 18.743
202312 25.168 130.500 26.152
202403 4.050 131.600 4.173
202406 7.588 133.000 7.736
202409 16.504 133.500 16.764
202412 15.146 135.100 15.202
202503 8.906 135.600 8.906

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (MEX:GSK N) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GSK Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines